Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Esophageal Cancer Active Surveillance (SANO-3)
NCT05491616Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2022
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in esophageal cancer and gastroesophageal junction cancer, sponsored by Erasmus MC. Started Sep 2022; status: active, not recruiting.
02
Drugs
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05491616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491616.